doi: 10.1016/j.diagmicrobio.2014.09.023.
Epub 2014 Oct 2.
Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections
Affiliations
- PMID: 25497419
- DOI: 10.1016/j.diagmicrobio.2014.09.023
Item in Clipboard
Antimicrobial treatment and outcomes of critically ill patients with OXA-48like carbapenemase-producing Enterobacteriaceae infections
Diagn Microbiol Infect Dis.
2015 Feb.
Abstract
We report on the clinical characteristics, antimicrobial therapy, and outcomes of 20 critically ill patients with severe OXA-48like infections. Carbapenem-based therapy demonstrated improved survival (odds ratio = 5.0) as compared with non-carbapenem therapy. Risk factors for mortality included Acute Physiology and Chronic Health Evaluation III score and length of stay, highlighting the significant influence of comorbidities and severity of underlying illness on outcomes.
Keywords: Carbapenemase-producing Enterobacteriaceae (CPE); Intensive care unit; Mortality; OXA-48; Treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Treating infections caused by carbapenemase-producing Enterobacteriaceae.Clin Microbiol Infect. 2014 Sep;20(9):862-72. doi: 10.1111/1469-0691.12697. Epub 2014 Jul 12. Clin Microbiol Infect. 2014. PMID: 24890393 Review.
-
Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.Diagn Microbiol Infect Dis. 2016 Oct;86(2):243-8. doi: 10.1016/j.diagmicrobio.2016.07.002. Epub 2016 Jul 7. Diagn Microbiol Infect Dis. 2016. PMID: 27519297
-
Carbapenem-resistant enterobacteriaceae: an emerging problem in children.Clin Infect Dis. 2012 Sep;55(6):852-9. doi: 10.1093/cid/cis543. Epub 2012 Jun 14. Clin Infect Dis. 2012. PMID: 22700827 Review.
-
Carbapenemase-producing Enterobacteriaceae.Semin Respir Crit Care Med. 2015 Feb;36(1):74-84. doi: 10.1055/s-0035-1544208. Epub 2015 Feb 2. Semin Respir Crit Care Med. 2015. PMID: 25643272 Free PMC article. Review.
-
Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins.Clin Microbiol Infect. 2015 Feb;21(2):179.e1-7. doi: 10.1016/j.cmi.2014.07.010. Epub 2014 Oct 13. Clin Microbiol Infect. 2015. PMID: 25599940
Cited by
-
Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection.Eur J Clin Microbiol Infect Dis. 2023 Dec;42(12):1485-1497. doi: 10.1007/s10096-023-04675-w. Epub 2023 Oct 27. Eur J Clin Microbiol Infect Dis. 2023. PMID: 37889370
-
Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa.Antimicrob Resist Infect Control. 2023 Apr 4;12(1):29. doi: 10.1186/s13756-023-01220-4. Antimicrob Resist Infect Control. 2023. PMID: 37013626 Free PMC article.
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
-
Carbapenemase-producing Enterobacteriaceae in Mexico: report of seven non-clonal cases in a pediatric hospital.BMC Microbiol. 2018 Apr 19;18(1):38. doi: 10.1186/s12866-018-1166-z. BMC Microbiol. 2018. PMID: 29673319 Free PMC article.
-
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Clin Microbiol Rev. 2018 Feb 14;31(2):e00079-17. doi: 10.1128/CMR.00079-17. Print 2018 Apr. Clin Microbiol Rev. 2018. PMID: 29444952 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
